Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab emtansine + vinorelbine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen of two anticancer agents used primarily in the treatment of HER2-positive metastatic breast cancer. Trastuzumab emtansine (also known as T-DM1 or ado-trastuzumab emtansine) is an antibody-drug conjugate that combines the HER2-targeted monoclonal antibody trastuzumab with the cytotoxic agent DM1 (emtansine), a microtubule inhibitor. Vinorelbine is a semi-synthetic vinca alkaloid that also acts as a microtubule inhibitor by interfering with tubulin polymerization, thereby inhibiting mitosis. The combination aims to enhance antitumor efficacy by targeting HER2-overexpressing tumor cells through two distinct mechanisms—antibody-mediated delivery of cytotoxic payload and direct disruption of cell division[2][4][5]. This regimen has been investigated in clinical trials for patients with pre-treated HER2-positive metastatic breast cancer[2].
- Brand names
- Kadcyla + Navelbine
- Other names
- T-DM1 + vinorelbineado-trastuzumab emtansine + vinorelbine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trastuzumab emtansine + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab emtansine + vinorelbine.